Venous Thromboembolic Disease Reduction with a Portable Pneumatic Compression Device
M. Froimson, T. Murray, A. Fazekas
Journal of Arthroplasty February 2009; 24(2): 310-316
Efficacy: The replacement of the standard IPC by ActiveCare® reduced VTE rate from 3.6% to 1.3%.
Length of Stay: The average LOS was shorter for patients treated with ActiveCare® than those treated with IPC (4.2 days vs. 5 days respectively).
Learn more about the study
What did the study compare?
The study compared the effectiveness of ActiveCare® Therapy to that of standard IPC when both treatments were used with Lovenox®. in preventing DVT in total joint replacements.
How was the study designed?
The study was a non-randomized, retrospective (sequential), comparative performance study of 1,577 patients. 1,354 patients used the standard IPC and 223 patients used ActiveCare.
How were the study results tested?
Patients had a duplex scan done for DVT detection at discharge and all symptomatic DVT/PE events were collected for up to 30 days postoperatively.
The replacement of the standard IPC by ActiveCare® Therapy significantly reduced the VTE rate from 3.6% to 1.3%: 70% risk reduction.